Adel Nada helped raise $177 million for GentiBio across two financing rounds. Then came a partnership carrying a possible $1.9 billion in future milestone payments. Those numbers make a tidy introduction. They also leave out an interesting part of the person: the executive leading the company had been thinking about how to make it easier for people to admit that something had gone wrong.
A fundraising announcement has little room for doubt. Everyone is pleased, delighted or thrilled; the future arrives wearing a freshly pressed suit. Nada has participated in that ritual. But he has also argued publicly that an organization needs people who can speak freely about failure. Read his career alongside that argument and a more useful portrait emerges: a founder whose work involves assembling the people, money and institutional relationships that let an uncertain idea become a company.
GentiBio remains a central chapter. His work now extends to venture building at Volnay, the chairmanship of Germany’s Akribion and a co-founder’s seat at FytonBio. The geography has widened. The practical question running through these roles is familiar: what does a promising research project need around it before it can stand on its own?
A long apprenticeship before the launch
Nada’s education took him through Alexandria University in Egypt and Rush University in Chicago, followed by advanced studies at the University of California, San Francisco, and the University of Basel. He also held an academic position at Rush. It is a career with several institutional accents, acquired before the startup announcements began.
His industry experience included senior positions at Abbott and Baxter, vice-presidential roles at Caladrius Biosciences and Intellia, and an executive role at Casebia. These are different settings for getting work done: established organizations with substantial infrastructure, and smaller businesses still putting their capabilities together. His later founder role followed that sequence of assignments rather than arriving straight from university.
By June 2019, Vycellix had named him to its inaugural scientific advisory board. His affiliation then was Casebia, the venture launched by Bayer and CRISPR Therapeutics. Alongside him were advisers from the University of Pennsylvania, Oslo University Hospital and Moffitt. The appointment provides an early glimpse of a pattern that would recur: Nada working across the boundary between an operating company and a wider circle of academic and industry colleagues.
Three institutions, one new company
When GentiBio announced its launch on August 5, 2020, it brought together $20 million in seed financing and exclusive licenses from three research institutions. OrbiMed, Novartis Venture Fund and RA Capital Management led the financing. Seattle Children’s Research Institute, Benaroya Research Institute and Israel’s MIGAL Galilee Research Institute supplied the licensed technologies.
The arrangement matters to Nada’s story because it makes the founder’s assignment unusually visible. The underlying work came from several places. A company had to gather the rights, maintain relationships with the originating teams and secure money to develop the combined work. Sponsored research collaborations were part of the plan. The scientists who had made the discoveries would remain involved.
That is a more populated origin story than the familiar lone-founder photograph suggests. David Rawlings, Jane Buckner and Gidi Gross were among the scientific co-founders identified at launch. Nada’s position was co-founder and chief executive. The distinction gives everyone their proper place: discovery, company formation and management were connected contributions, with different people carrying different responsibilities.
What $157 million was supposed to buy
A year later, on August 11, 2021, GentiBio announced a $157 million Series A led by Matrix Capital Management. Avidity Partners joined the round, alongside returning seed investors and other participants. The company reported that it had raised $177 million since 2020. The arithmetic is straightforward; the organizational consequences were considerable.
Nada described a business of about 17 people, with plans to reach roughly 100 over the following 18 months. That was an ambition stated at the time, rather than a subsequent headcount. The expansion plan included research and corporate capabilities in Boston and manufacturing in Seattle. Funding was being translated into a map of work, locations and future colleagues.
The difference between 17 people and a planned 100 is also the difference between knowing nearly every conversation and needing an organization that can function without the chief executive in every conversation. A round of that size made hiring and coordination central parts of the assignment. A company can announce new capital in a morning. Turning it into an effective working group takes rather longer than the congratulatory messages.
$177M across the two rounds. Bar lengths compare round sizes.
The billion-dollar number has conditions
On August 10, 2022, GentiBio announced a collaboration with Bristol Myers Squibb. The agreement gave BMS the right to develop and advance up to three resulting programs. There was an upfront cash payment, whose size was undisclosed, and eligibility for up to $1.9 billion in development and sales milestones, plus royalties.
Each part of that sentence does a different job. The upfront payment was cash at the beginning of the arrangement. Milestones depended on future events. Royalties were another potential stream. The $1.9 billion figure described conditional future payments; it was neither GentiBio’s fundraising total nor Nada’s personal fortune. Large numbers become more interesting when their labels stay attached.
For Nada, the agreement added a different kind of relationship to the business he had helped establish. Investors had financed the company. A commercial partner had now agreed to work with it under a defined development arrangement. His own account of the choice emphasized BMS’s established capabilities. It is a revealing emphasis for an executive whose career had already included both large organizations and younger companies: the partner’s ability to do the work belonged in the decision.
Potential future development and sales milestones under the 2022 BMS agreement. The upfront payment was undisclosed; royalties were additional.
Room for an unwelcome answer
During that period, Nada set out a management argument that was less ceremonial than a financing announcement. In January 2022, he wrote about accepting setbacks, improving through iteration and enabling colleagues at every level to speak up. He wanted an organization that could recognize problems earlier and learn from them at lower cost.
“If we are not failing, we are not daring.”
Adel Nada, January 2022
The aspiration gives the financial story a human dimension. A founder can arrange licenses and recruit investors; colleagues still need permission to deliver an unwelcome answer. Nada’s argument placed that responsibility on the organization. His public comments about former colleagues offer another, smaller view of his managerial voice. On LinkedIn, he praised Adam Chicoine’s expertise and urged prospective employers to recruit him. The endorsement was specific, practical and directed toward someone else’s next opportunity.
Taking experience to another boardroom
In May 2023, Alia Therapeutics announced Nada’s appointment as an independent board director. The Italian company’s chief executive was Letizia Goretti. Paola Pozzi of Sofinnova Partners, also a board member, pointed to the experience he would bring to the company’s next stage. Nada expressed an interest in helping advance its platform and pipeline.
It was a move into a different seat at the table. The chief executive runs the company; an independent director brings judgment and oversight from outside its daily management. For someone who had already assembled a startup and negotiated its financing relationships, the appointment offered a way to apply that experience without repeating the same job title.
Akribion’s public emergence in February 2025 made the pattern more explicit. The German company announced €8 million in seed financing and Nada’s appointment as board chair. Michael Krohn and Lukas Linnig were its co-founders and co-chief executives. CARMA FUND and RV Invest led the round. Akribion had been founded in 2024 as a spinout from BRAIN Biotech and was based in Zwingenberg. Nada joined to support a management team already in place.
A founder again, with a different assignment
Later in 2025, another chapter appeared in Australia. FytonBio was among the first three companies backed by the Monash Ventures Pre-Seed Fund. Monash identified Nada as a co-founder alongside Associate Professor Remy Robert and Chuck Silberstein. Breakthrough Victoria’s account also identified co-founder Chacko Joseph, with Silberstein serving as chief executive and Nada as executive chair.
The investment was A$1 million, split equally between Monash and Breakthrough Victoria. FytonBio held rights to Monash technology, with the university and Robert retaining ownership interests. The structure brings Nada back to the kind of company formation visible at GentiBio: university work, defined commercial rights, external capital and a team with distinct jobs.
At Volnay, where he is a venture partner, that assembly process is the business model. The organization supplies initial capital, interim leadership and execution support to new ventures. Stefan Wildt, Ulrik Nielsen and Johannes Fruehauf are among its co-founders. Its team spans development, manufacturing, legal work and finance. Nada’s place is among people building the machinery around new companies.
His career now contains several versions of the founder’s job: running a company, chairing its board, backing its formation and advising its leaders. GentiBio’s current president and chief executive is Andy Walker. Nada’s next chapters are already taking shape elsewhere. The through-line is the work of getting people and institutions to commit to a project, then giving that project an organization capable of learning as it goes.
Keep reading
PEOPLE, COMPANIES & FURTHER READING